Literature DB >> 1359485

Extrapyramidal symptoms are serious side-effects of antipsychotic and other drugs.

D T Blair1, A Dauner.   

Abstract

Antipsychotic medications commonly produce extrapyramidal symptoms as side effects. The extrapyramidal symptoms include acute dyskinesias and dystonic reactions, tardive dyskinesia, Parkinsonism, akinesia, akathisia, and neuroleptic malignant syndrome. Extrapyramidal symptoms are caused by dopamine blockade or depletion in the basal ganglia; this lack of dopamine often mimics idiopathic pathologies of the extrapyramidal system. Less recognized is that extrapyramidal symptoms are also associated with certain non-antipsychotic agents, including some antidepressants, lithium, various anticonvulsants, antiemetics and, rarely, oral-contraceptive agents. Extrapyramidal symptoms caused by these agents are indistinguishable from neuroleptic-induced extrapyramidal symptoms. Clinicians must be able to recognize these side effects and be able to determine the antipsychotic-induced and non-antipsychotic causes of extrapyramidal symptoms.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359485     DOI: 10.1097/00006205-199211000-00018

Source DB:  PubMed          Journal:  Nurse Pract        ISSN: 0361-1817


  9 in total

1.  Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges.

Authors:  Jin-Ku Lee; DO-Hyun Nam; Jeongwu Lee
Journal:  Oncol Lett       Date:  2016-01-07       Impact factor: 2.967

Review 2.  Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders.

Authors:  Chad R Johnson; Brian D Kangas; Emily M Jutkiewicz; Jack Bergman; Andrew Coop
Journal:  Biomedicines       Date:  2022-02-07

Review 3.  Aripiprazole (ABILIFY MAINTENA®): a review of its use as maintenance treatment for adult patients with schizophrenia.

Authors:  Matt Shirley; Caroline M Perry
Journal:  Drugs       Date:  2014-07       Impact factor: 9.546

4.  Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action.

Authors:  J E Olijslagers; T R Werkman; A C McCreary; C G Kruse; W J Wadman
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

5.  Investigation of motor self-monitoring deficits in schizophrenia with passivity experiences using a novel modified joint position matching paradigm.

Authors:  Chi Sing Law; Yi Nam Suen; Wing Chung Chang; Sherry Kit Wa Chan; Edwin Ho Ming Lee; Christy Lai Ming Hui; Eric Yu Hai Chen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-04-10       Impact factor: 5.270

6.  Novel Antimuscarinic Antidepressant-like Compounds with Reduced Effects on Cognition.

Authors:  Chad R Johnson; Brian D Kangas; Emily M Jutkiewicz; Gail Winger; Jack Bergman; Andrew Coop; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2021-03-12       Impact factor: 4.402

7.  Characteristics of Patients Experiencing Extrapyramidal Symptoms or Other Movement Disorders Related to Dopamine Receptor Blocking Agent Therapy.

Authors:  Shaina Musco; Laura Ruekert; Jaclyn Myers; Dennis Anderson; Michael Welling; Elizabeth Ann Cunningham
Journal:  J Clin Psychopharmacol       Date:  2019 Jul/Aug       Impact factor: 3.153

8.  Dose Effects of Histone Deacetylase Inhibitor Tacedinaline (CI-994) on Antipsychotic Haloperidol-Induced Motor and Memory Side Effects in Aged Mice.

Authors:  Bryan McClarty; Guadalupe Rodriguez; Hongxin Dong
Journal:  Front Neurosci       Date:  2021-10-06       Impact factor: 5.152

9.  Neurological melioidosis (Burkholderia pseudomallei) in a chronic psychotic patient treated with antipsychotics: A case report.

Authors:  Guan-Bo Chen; Sheng-Hui Tuan; Li-Hsiang Chen; Wen-Sou Lin
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.